• Dogan Yazilitas, Hayriye Sahinli, Guleser Saylam, Goksen Inanc Imamoglu, Mehmet Hakan Korkmaz, and Omer Bayir.
• Department of Medical Oncology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, <br> Ankara, Turkiye.
• J Coll Physicians Surg Pak. 2023 Apr 1; 33 (4): 469473469-473.

ObjectiveTo examine the treatment outcomes of the EXTREME regimen as the first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck.Study DesignObservational study. Place and Duration of the Study: Department of Medical Oncology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Turkiye, between January 2014 and December 2021.MethodologyA total of 60 patients with recurrent/metastatic head and neck cancers were treated with EXTREME regimen. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to determine the factors associated with progression-free survival (PFS) and overall survival (OS).ResultsPatients receiving cetuximab in combination with chemotherapy for metastatic or unresectable disease were obtained from patient files and electronic medical records. Majority of patients were male (78.3%). The median PFS of patients was 7 months. The median survival of the patients was 9.06 months. During follow-up, 55 patients (91.7%) relapsed, and 51 patients (85%) died. The median survival of patients with eastern cooperative oncology group (ECOG) performance status 0, 1, and 2 was 16, 9, and 4 months, respectively. And the survival of patients was found significantly lower with lower ECOG performance scores.ConclusionOS was determined as 9.06 months. ECOG performance score had an important effect on the survival.Key WordsCetuximab, Head and neck cancer, Chemotherapy.

17 keywords...

hide…